INTOPSENS - a highly INTegrated OPtical SENSor for point of care label free identification of pathogenic bacteria strains and their antibiotic resistance.
Sepsis is a bacterial infection in the blood. It is a life-threatening condition, characterized by multi-organ failure. In the EU alone, sepsis claims 146,000 lives/year and is responsible for EUR 7.6 billion/year health care costs.
InTopSens is a multidisciplinary project involving the emerging fields of photonics structures, electronics, fluidics and bio-chemistry, to contribute to the development of high value sensor technology for a fast and low-cost diagnosis of sepsis.
This objective will be addressed through the demonstration of a compact polymer and silicon-based CMOS-compatible photonics sensor system. It integrates two label-free biomolecular recognition photonic sensor technologies with sensitivities as low as 0.1ng per ml, state-of-the-art in label-free integrated optical biosensors, with novel coupling technology that will permit very high integration of hundreds of sensing areas on a 1mm2photonics chip.
INTOPSENS creates disposable lab-on-chip cartridges with integrated microfluidic sample preparation and ultrasensitive photonic transducers, as well as a bench-top readout system. Focuses on a rapid solution (<1h) with little hands-on time, so as to be used at point of care (PoC) in an intensive care unit by paramedics and general practitioners. Chiropractor in Garland. Consists of five research centres and two industry partners from six European countries. Was supported during 2008-2012 with 2.6 Million Euro by the European Union through its Seventh Framework Programme. research chemicals